Professor, Internal Medicine, Washington University School of Medicine
Oncology
Dr. Nancy L. Bartlett, MD
|
|
Give Review
Nancy Bartlett practices Oncology. He graduated from Washington University School of Medicine in St. Louis. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Nancy Bartlett is a published physician. He published 63 publications, including: 'A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).'
Publications
- The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
- A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell Lymphoma (DLBCL).
- Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
- Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin Lymphoma in the modern era.
- A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory Lymphoma.
- A Young Woman With Blurred Vision and Distal Paresthesias.
- Blinatumomab for the treatment of B-cell Lymphoma.
- Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
- Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell Lymphoma relapsing after rituximab, cycloph...
- Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell Lymphoma.
- Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies.
- Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study.
- Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma.
- Limited utility of routine surveillance imaging for classical hodgkin Lymphoma patients in first complete remission.
- CD163 Immunohistochemistry Is Superior to CD68 in Predicting Outcome in Classical Hodgkin Lymphoma.
- Objective responses in relapsed T-cell Lymphomas with single agent brentuximab vedotin.
- Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
- Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective Analysis from two US academic medical centers.
- Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive Lymphomas: a retrospective evaluation of safety and efficacy.
- High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective Analysis.
- Anaplastic large-cell Lymphoma with aberrant expression of multiple cytokeratins masquerading as metastatic carcinoma of unknown primary.
- Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis.
- Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma-"DO NO HARM".
- Non-Hodgkin's Lymphomas, Version 1.2013.
- Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative Analysis from a large North American co-operative group trial.
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Co...
- Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell Lymphoma.
- Assessment of Cellular Proliferation in Tumors by PET Using 18F-ISO-1.
- The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive Analysis from the N...
- The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Al...
- Brentuximab vedotin in relapsed/refractory hodgkin Lymphoma: commentary.
- A Phase 1 Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies.
- A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell Lymphoma.
- A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin Lymphoma.
- Extended Retreatment with Brentuximab Vedotin (SGN-35) Maintains Complete Remission in Patient with Recurrent Systemic Anaplastic Large-Cell Lymphoma.
- Composite diffuse large B-cell Lymphoma and precursor B lymphoblastic Lymphoma presenting as a double-hit Lymphoma with MYC and BCL2 translocation.
- Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin Lymphoma treated with standard salvage chemotherapy and autologous stem cell transplanta...
- Role of routine imaging in Lymphoma.
- 18F-FDG PET/CT for early response assessment in diffuse large B-cell Lymphoma: poor predictive value of international harmonization project interpretation.
- Doxorubicin, vinblastine, gemcitabine (CALGB 50203) for stage I/II non-bulky Hodgkin Lymphoma: pretreatment prognostic factors and interim PET.
- Brentuximab vedotin (SGN-35) for relapsed CD30-positive Lymphomas.
- Anti-CD30 Antibodies for Hodgkin Lymphoma.
- The present: optimizing therapy--too much or too little?
- Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin Lymphoma: results from a Multicenter Study.
- Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell Lymphoma: CALGB 59909.
- Something old, something new: options for treating relapsed mantle cell Lymphoma.
- Protein losing enteropathy associated with follicular Lymphoma of the small bowel.
- Modern treatment of Hodgkin Lymphoma.
- Salvage regimens for Hodgkin Lymphoma.
- A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.
- Management of advanced stage Hodgkin's Lymphoma.
- Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy.
- Antibodies for the treatment of diffuse large cell Lymphoma.
- Rituximab in lymphocyte-predominant Hodgkin Disease: results of a phase 2 trial.
- Interdigitating dendritic reticulum Cell tumor of lymph nodes: case report with differential diagnostic considerations.
- Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's Lymphoma and mild thrombocytopenia.
- Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
- Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin Lymphoma and mild thrombocytopenia: a phase II multicenter trial.
- Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-g...
- Stanford V and radiotherapy for locally extensive and advanced Hodgkin's Disease: mature results of a prospective clinical trial.
- Limited-Stage Hodgkin Lymphoma.
- A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative Analyses of patient-specific factors.
Schools
Washington Center School of Medicine
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- American Enterprise Group
- American Republic
- Assurant Health
- Benesys
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Health and Life PPO
- Coventry Health Care of Missouri PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- HealthLink PPO
- Homestate Health Plan
- Choice Care PPO
- Medicaid
- Medicare MCR
- Medico
- MultiPlan PPO
- PHCS Network PPO
- Old Surety Life Insurance CompanyMedicare MCR
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Stanford University -
UCSF -
Washington University School of Medicine in St. Louis
Hospital
-
Barnes-Jewish Hospital
Drug Facts
| NPI NUMBER | 1316965759 | |
| NPPES Provider LastName | BARTLETT | |
| NPPES Provider FirstName | NANCY | |
| NPPES Provider ZIPCode | 631101032 | |
| NPPES Provider State | MO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 883.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 111.0 | |
| Percent Opioid Claims | 12.57 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1316965759 |
| Last Name Of The Provider | BARTLETT |
| First Name Of The Provider | NANCY |
| View All |
Similar Doctors
|
|
Dr. Mary M. Klix, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy P. Rearden, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Craig R. Hildreth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel Picus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William J. Moriconi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Todd A. Fehniger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle Z. Schultz, MD |
|
|
Dr. Bryan A. Faller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce J. Roth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy A. Graubert, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ravi Vij, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|